SCHEMBL678848

SCHEMBL678848

CC(=O)CN(CC(C)=O)N=O

nearest known ligand 0.43

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.43
ALDH1A1 P00352 3/20 0.35
TDP1 Q9NUW8 1/20 0.35
TRPA1 O75762 1/20 0.33
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29579799 0.86 TSHR (0.39) TSHRALDH1A1TDP1
SCHEMBL3502068 0.83 TSHR (0.40) TSHRALDH1A1TDP1
SCHEMBL30131178 0.79 ALDH1A1 (0.33) TSHRALDH1A1
SCHEMBL3344974 0.74
SCHEMBL441470 0.71
SCHEMBL25278306 0.69
Hydrochloric Acid SCHEMBL2672014 0.69
SCHEMBL31438419 0.69 ALDH1A1 (0.39) TSHRALDH1A1TDP1TRPA1
SCHEMBL416818 0.67 TRPA1 (0.50) TSHRALDH1A1TDP1TRPA1HTT
Propane SCHEMBL29212693 0.67 ALDH1A1 (0.44) ALDH1A1TDP1TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025024565-A1 CONTROLLED EXPANSION OF SORBENT POLYMER COMPOSITE ARTICLE W. L. GORE & ASSOCIATES, INC. (US) 2025-01-30 WO disclosed
US-20250032976-A1 CONTROLLED EXPANSION OF SORBENT POLYMER COMPOSITE ARTICLE GORE & ASS (US) 2025-01-30 US disclosed
CN-117312159-A Test data construction method and device and storage medium 广发证券股份有限公司 2023-12-29 CN disclosed
CN-116637073-A Active oxygen active nitrogen responsive nano composite micelle, preparation method thereof and nano medicine carrying micelle 澳门大学 2023-08-25 CN disclosed
CN-116019596-A Manufacturing method of liver and lung metastasis animal model for inducing pancreatic cancer through BOP 南方医科大学深圳医院 2023-04-28 CN disclosed
CN-116019596-A Manufacturing method of liver and lung metastasis animal model for inducing pancreatic cancer through BOP 南方医科大学深圳医院 2023-04-28 CN disclosed
CN-113929903-B Method for preparing terminal group high-fidelity polypeptide by NPCA polymerization initiated by protonated amino group 中国科学技术大学 2022-10-28 CN disclosed
EP-2156188-B1 INDUCTION OF DIFFERENTIAL STRESS RESISTANCE AND USES THEREOF UNIV SOUTHERN CALIFORNIA (US) 2021-05-05 EP disclosed
US-10821177-B2 Induction of differential stress resistance and uses thereof UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2020-11-03 US disclosed
US-20160369237-A1 METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY ADVANCED CELL TECH INC (US) 2016-12-22 US disclosed
US-20030100564-A1 Novel methods for inhibiting angiogenesis THE INSTITUTE FOR CANCER RESEARCH 2003-05-29 US disclosed
WO-2003028715-A2 METHODS USING 1, 2-DITHIOL-3-THIONES AND THEIR DERIVATIVES AND METABOLITES FOR INHIBITING ANGIOGENESIS CEPHALON, INC. (US) 2003-04-10 WO disclosed
EP-1229908-A1 USE OF NSAIDs FOR THE TREATMENT OF PANCREATIC CANCER ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, Inc. (US) 2002-08-14 EP disclosed
WO-2001035956-A1 USE OF NSAIDs FOR THE TREATMENT OF PANCREATIC CANCER ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE, INC. (US) 2001-05-25 WO disclosed
US-6197796-B1 Anticancer composition comprising a diaminotrifluoromethylpyridine derivative ISHIHARA SANGYO KAISHA LTD. (JP) 2001-03-06 US disclosed
US-6132708-A Liver regeneration using pancreas cells OREGON HEALTH SCIENCES UNIVERSITY (US) 2000-10-17 US disclosed
EP-1021523-A1 LIVER REGENERATION USING PANCREAS CELLS OREGON HEALTH SCIENCES UNIVERSITY (US) 2000-07-26 EP disclosed
EP-0971711-A1 ANTICANCER COMPOSITION COMPRISING A DIAMINOTRIFLUOROMETHYLPYRIDINE DERIVATIVE ISHIHARA SANGYO KAISHA, LTD. (JP) 2000-01-19 EP disclosed
WO-1999019461-A1 LIVER REGENERATION USING PANCREAS CELLS OREGON HEALTH SCIENCES UNIVERSITY (US) 1999-04-22 WO disclosed
WO-1998037887-A1 ANTICANCER COMPOSITION COMPRISING A DIAMINOTRIFLUOROMETHYLPYRIDINE DERIVATIVE ISHIHARA SANGYO KAISHA LTD. (JP) 1998-09-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100564-A1 Novel methods for inhibiting angiogenesis TEK, TXNRD3, FLT4 TSHR 810/4885ALDH1A1 127/4885TDP1 3280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.